Ganciclovir Injection, Powder, Lyophilized, For Solution
Product Images NDC 70436-089

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 70436-089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structures (Image 01)

Chemical structures of ganciclovir sodium and ganciclovir are shown, each with their respective molecular formulas and molecular weights. Ganciclovir sodium has the formula C9H12N5NaO4 and a molecular weight of 277.22, while ganciclovir has the formula C9H13N5O4 and a molecular weight of 255.23.*

FDA Label Image

Figure 1 (Image 02)

A line graph titled 'ICM 1653: Time to Progression of CMV Retinitis' comparing the proportion without progression over time from the start of maintenance therapy (days) between intravenous (IV) and oral administration. The graph shows the proportion without progression decreasing over a 150-day period, with separate lines for IV and oral routes.*

FDA Label Image

Figure 2 (Image 03)

A line chart titled 'ICM 1774: Time to Progression of CMV Retinitis' comparing the proportion without progression over time (days from start of maintenance therapy) between intravenous (IV) and oral administration. The y-axis shows proportion without progression, decreasing from 1 to 0, and the x-axis shows time from 0 to 120 days. The IV group (dashed line) maintains a higher proportion without progression compared to the oral group (solid line) throughout the period.*

FDA Label Image

Figure 3 (Image 04)

A line graph titled 'AVI 034: Time to Progression of CMV Retinitis' comparing the proportion of patients without disease progression over time in days from the start of maintenance therapy. Two treatment routes are shown: intravenous (IV) indicated by a dashed line and oral by a solid line.*

FDA Label Image

Principal Display Panel (Vial Label)

Label for Ganciclovir for Injection, USP 500 mg per vial lyophilized powder for intravenous infusion by Slate Run Pharmaceuticals, LLC. The label indicates injection preparation instructions, caution about cytotoxicity, storage conditions at 25°C, and barcode with NDC 70436-089-55.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.